Every 8-K that Bionano Genomics, Inc. (BNGO) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow BNGO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BNGO filings page.
Bionano Genomics, Inc. reported second quarter 2026 results with continued growth in its optical genome mapping business. For the three months ended June 30, 2026, total revenue was $8.2 million, up 21% from $6.7 million a year earlier, driven largely by consumables and clinical adoption. Consumables revenue reached $4.3 million, up 31%, and 9,219 nanochannel array flow cells were sold, a 27% increase over 7,233 in 2025. GAAP gross margin was 53% versus 52% a year ago, while operating expenses rose 2% to $11.5 million; total adjusted operating expense declined 2% to $8.7 million. The company recorded a GAAP net loss of $7.4 million for the quarter and $15.7 million for the first half of 2026. Management highlighted the completed full retirement of all outstanding Senior Secured Convertible Debentures, eliminating secured debt and related liens, and cited strong growth in OGM-related publications and conference activity. Guidance calls for Q3 2026 revenue of $8.2–$8.6 million and full-year 2026 revenue of $31–$33 million.
Bionano Genomics, Inc. announced the appointment of Alex Hastie, Ph.D. as Chief Scientific Officer, effective July 20, 2026. He will lead global scientific strategy, innovation, and research initiatives focused on expanding applications of the company’s optical genome mapping (OGM) technologies in research and clinical genomics.
Hastie previously spent 14 years at Bionano and was a key contributor to the development of its core OGM platforms. Several leading academic and clinical genomics experts are quoted expressing strong support for his return, highlighting his deep expertise and long-standing role in advancing OGM.
Bionano Genomics, Inc. reported that its Chief Medical Officer, Alka Chaubey, Ph.D., has resigned. The resignation was submitted on June 2, 2026 and will be effective July 5, 2026. The company is incorporated in Delaware and its common stock trades on the Nasdaq Capital Market under the symbol BNGO.
Bionano Genomics has fully repaid its Senior Secured Convertible Debentures, removing all secured debt from its balance sheet. The company used cash on hand to retire and cancel debentures with an aggregate face value of $20,000,000, originally issued in May 2024 and repaid at their scheduled maturity on May 26, 2026.
All liens on Bionano’s assets and the associated restrictive covenants have been terminated, which the company says provides meaningfully greater financial and operational flexibility. Management describes the debt retirement as a significant milestone that simplifies the financial profile and allows more focus on growing adoption of its optical genome mapping solutions and executing its commercial strategy.
Bionano Genomics, Inc. held its 2026 Annual Meeting of Stockholders and reported voting results on three proposals. As of the March 19, 2026 record date, 11,091,615 common shares were outstanding and entitled to vote, with 4,225,995 shares represented, or about 38.1% participation.
Stockholders elected Class II directors Albert Luderer, Ph.D. and Kristiina Vuori, M.D., Ph.D., each to serve until the 2029 annual meeting or earlier departure. They also approved, on an advisory basis, compensation of named executive officers and ratified BDO USA, P.C. as independent auditor for the fiscal year ending December 31, 2026.
Bionano Genomics reported Q1 2026 revenue of $6.7 million, up 4% from $6.5 million a year earlier, with improving margins but a wider loss. Gross margin reached 49%, compared to 46% in Q1 2025, supported by higher consumables use and services.
Consumables revenue was $3.9 million, up 20%, and the company sold 8,178 nanochannel array flow cells, a 17% increase. Operating expenses declined 2% to $11.1 million, but net loss widened to $8.3 million from $3.1 million, partly reflecting weaker other income.
Bionano highlighted reimbursement tailwinds, including a new Category I CPT code 81354 effective January 1, 2026 and a 47% payment increase for CPT code 81195 to $1,853.22. The company guided Q2 2026 revenue to $7.5–$7.8 million and full-year 2026 revenue to $30–$33 million, and reiterated expectations to retire its secured convertible debt.
Bionano Genomics, Inc. removed R. Erik Holmlin, Ph.D. as president and chief executive officer effective May 5, 2026, and he also resigned from the board. He will receive severance under his employment agreement and is expected to serve as an advisor/consultant during the transition.
The board appointed chairman Albert A. Luderer, Ph.D. as interim chief executive officer and interim principal financial officer, while he continues as board chair. Under an offer letter dated May 6, 2026, he will receive a $600,000 annual base salary, up to a $400,000 pro-rated 2026 incentive bonus, and a $4,000 monthly housing and travel stipend.
Christopher J. Twomey was named Lead Independent Director and joined the compensation committee. The company plans to conduct a search for a permanent CEO and stated it anticipates a seamless leadership transition without business disruption.
Bionano Genomics reported Q4 2025 revenue of $8.0M, down 3% from Q4 2024, with gross margin improving to 43%. For full-year 2025, revenue was $28.5M, a 7% decline from 2024 as instrument and discontinued clinical services revenue fell, partly offset by higher consumables and software revenue.
Full-year gross margin rose sharply to 46% from 1%, and operating expenses dropped 55% to $46.5M, reducing net loss to $26.4M from $112.0M. The company ended 2025 with $29.6M in cash, equivalents, investments and restricted short-term investments and guided 2026 revenue to $30–33M, with Q1 2026 guidance of $6.5–6.7M.
Bionano Genomics, Inc. filed a current report to disclose that it issued a press release with preliminary financial results for the fourth quarter and full fiscal year ended December 31, 2025. The press release is provided as Exhibit 99.1, giving an early look at the company’s performance for that period. The report specifies that this preliminary financial information is being furnished, not filed, which limits its use for certain legal purposes. The document is signed on behalf of Bionano Genomics by President and Chief Executive Officer R. Erik Holmlin, Ph.D.
Bionano Genomics filed a Form 8-K stating it issued a press release reporting financial results for the third quarter ended September 30, 2025. The release is furnished under Item 2.02 and attached as Exhibit 99.1. In accordance with General Instruction B.2., the information in Item 2.02, including Exhibit 99.1, is furnished and not deemed “filed” for purposes of Section 18 of the Exchange Act, nor incorporated by reference into other filings unless specifically referenced.
Bionano Genomics, Inc. filed a Form 8-K reporting a material corporate event and attached transaction documents. The filing lists exhibit materials that include the Form of Pre-Funded Warrant, Form of Series E/F Warrant, and a Form of Securities Purchase Agreement. It also includes two press releases: one dated September 16, 2025 announcing the pricing of an Offering, and one dated September 17, 2025 announcing the closing of the Offering. The filing provides the company’s registered details and Nasdaq listing (BNGO) but does not disclose transaction amounts, share counts, or other financial terms within the text provided.
Bionano Genomics, Inc. filed a Form 8-K reporting that on August 14, 2025 it issued a press release containing its financial results for the quarter ended June 30, 2025. The filing states the full press release is attached as Exhibit 99.1 to the report and notes that, consistent with applicable SEC guidance, the press release and related information are furnished rather than "filed" and are therefore not subject to Section 18 liabilities or automatically incorporated by reference into other SEC filings. The 8-K also contains a standard forward-looking statements caution describing assumptions, risks (including financing needs and geopolitical and macroeconomic uncertainty) and the possibility that actual results may differ materially from expectations.
Bionano Genomics (NASDAQ: BNGO) has filed an 8-K/A to amend its previous filing from June 13, 2025, correcting voting results for two key proposals. The amendment specifically addresses errors in reporting Broker Non-Votes and Votes For on Proposals 3 and 4.
Key Corrections:
- Proposal 3 (Ratification of BDO USA as auditor): Corrected to show 0 Broker Non-Votes instead of previously reported 769,744
- Proposal 4 (Warrant Exercise Share Issuance): Updated to show 396,176 Votes For (previously 369,176) and 769,744 Broker Non-Votes (previously unreported)
The corrections do not affect the outcome of either vote. Proposal 4 approved the issuance of up to 661,374 shares of common stock related to warrant exercises from a January 3, 2025 securities purchase agreement with institutional investors, in compliance with Nasdaq Listing Rule 5635(d).